Your browser doesn't support javascript.
loading
Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021.
Cui, Xiaoni; Wang, Pengxiang; Wei, Zhun.
Afiliação
  • Cui X; Sino-Cell Biomed Co., Ltd., Qingdao, Shandong, China.
  • Wang P; Sino-Cell Biomed Co., Ltd., Qingdao, Shandong, China.
  • Wei Z; Institute of Innovative Drugs and Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, Shandong, China.
Drug Discov Ther ; 15(4): 222-224, 2021 Sep 22.
Article em En | MEDLINE | ID: mdl-34275974
In December 2019, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of coronavirus disease 2019 (COVID-19), and the resulting pandemic has caused widespread health problems and social and economic disruption. Thus far in 2021, more than 4 million people worldwide have died from COVID-19, so safe and efficacious vaccines are urgently needed to restore normal economic and social activities. According to the official guidance documents of the World Health Organization (WHO), vaccines based on four major strategies including mRNA, adenoviral vectors, inactivated viruses, and recombinant proteins have entered the stage of emergency use authorization and pre-certification evaluation. The current review summarizes these vaccines and it looks ahead to the development of additional COVID-19 vaccines in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Revista: Drug Discov Ther Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Aprovação de Drogas / Vacinas contra COVID-19 / COVID-19 Limite: Humans Idioma: En Revista: Drug Discov Ther Ano de publicação: 2021 Tipo de documento: Article